

General description

INN	Vinblastine
ATC codes	L01CA01
Medicine type	Chemical agent
EML status history	First added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites Added in 2015 (TRS 994) for Hodgkin lymphoma Added in 2015 (TRS 994) for Kaposi sarcoma of unspecified primary site Added in 2015 (TRS 994) for Germ cell tumour of testis Added in 2015 (TRS 994) for Other specified malignant neoplasms of the ovary Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites Added in 2021 (TRS 1035) for Other specified gliomas of brain Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative Added in 2023 (TRS 1049) for Langerhans cell histiocytosis
Wikipedia	Vinblastine 
DrugBank	Vinblastine 

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

- Hodgkin lymphoma
- Kaposi sarcoma of unspecified primary site
- Germ cell tumour of testis
- Other specified malignant neoplasms of the ovary
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Other specified gliomas of brain
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Langerhans cell histiocytosis



